Sovaldi

Could Gilead’s Sovaldi be the answer to COVID-19 coronavirus?

https://pharmaphorum.com/news/could-gileads-sovaldi-be-the-answer-to-coronavirus/

Gilead needs deal-maker CEO after Milligan quits

https://pharmaphorum.com/news/gilead-needs-deal-maker-ceo-after-milligan-quits-analyst/

Zepatier to add competition to Europe’s hep C market

https://pharmaphorum.com/news/zepatier-add-competition-europes-hep-c-market/

Many millions still untreated – but hep C boom is already over

https://pharmaphorum.com/views-and-analysis/many-millions-left-untreated-hepatitis-c-boom-already/

Gilead hopes cut-price pan-genomic hep C combo will revive sales

https://pharmaphorum.com/transversal-categories/us/gilead-looks-new-hepatitis-c-combo-boost-sales/

Raising the bar: can Gilead’s next challenge be even bigger than Hep C?

https://pharmaphorum.com/views-and-analysis/raising-the-bar-can-gilead-s-next-challenge-be-even-bigger-than-hep-c/

Close in 10 seconds

Pharmaphorum.com

Search